A new drug combo for head and neck cancer before surgery
Treatments studied
Part of Cancer, Ear, nose & throat clinical trials.
This trial tests two drugs, GV20-0251 and Sintilimab, given before surgery for head and neck cancer. The goal is to see if this combination can shrink tumors and make surgery more effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have a newly diagnosed, advanced head and neck cancer (not nasopharyngeal, salivary gland, or thyroid) that can be removed with surgery.
- You are generally well enough to be up and about (ECOG score 0 or 1).
- Your blood counts, liver, kidney, and clotting functions are within acceptable ranges.
- You have not had prior treatment with certain immune or targeted therapies, and you are not taking high-dose steroids or other immune-suppressing drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (becotatug vedotin, pucotenlimab, and cisplatin) given before surgery for head and neck cancer that has not spread far. The goal is to see if this treatment shrinks tumors and improves outcomes for patients with stage 3 or 4A disease.
This trial compares two immunotherapy drugs (ivonescimab vs. pembrolizumab) given before and after surgery for head and neck cancer that can be surgically removed. The goal is to see which drug works better to shrink the tumor and prevent the cancer from coming back.
This trial tests two medications given before surgery for head and neck cancer. The goal is to see if shrinking the tumor beforehand improves outcomes. If you have operable head and neck squamous cell cancer and are generally healthy, you may be eligible.
This trial tests whether giving immunotherapy along with chemotherapy before surgery can help treat locally advanced head and neck cancer that can be removed. The goal is to see if this combination shrinks tumors and improves outcomes.
This trial tests a combination of immune therapy, targeted drugs, and a virus-based treatment before surgery for head and neck cancer that has spread to lymph nodes. The goal is to see if this approach can shrink the tumor and improve outcomes.
This trial tests a drug called sintilimab (an immunotherapy that boosts your immune system to fight cancer) given before and after surgery for head and neck cancer that can be removed. The goal is to see if adding sintilimab to surgery helps reduce the chance of cancer coming back.
Hear when a new Head and Neck Squamous Cell Carcinoma HNSCC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.